Drug Trial Radar · NCT07600736
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of ABS-1230 in Pediatric and Young Adult Participants With KCNT1-related Epilepsy
Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
61
Planned (sponsor's estimate)
Start
May 18, 2026
Primary completion
Jan 2027
Study completion Jan 2028
Sponsor
- Lead sponsor
- Actio Biosciences, Inc.Industry
- Sponsor type
- Industry
- First posted
- May 22, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 1 month, up to 21 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial will evaluate the safety, tolerability, pharmacokinetics, and clinical activity of ABS-1230 compared with placebo in participants with KCNT1-related epilepsy
Conditions
- KCNT1-Related Epilepsy
Interventions
ABS-1230Drug
Daily
PlaceboDrug
Daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Safety and tolerability of ABS-1230 (incidence and severity of adverse events)Time frame: Measured from Day 1 to End of Study or Early Termination (up to 12 weeks)
- Part 2: Efficacy of ABS-1230Time frame: Measured from Day 1 to End of Study or Early Termination (up to 12 weeks)
- Part 3: Safety and tolerability of ABS-1230 (incidence and severity of adverse events)Time frame: Measured from Day 1 of Part 3 to End of Study or Early Termination (up to 1 year)
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Northeast Regional Epilepsy Group
Hackensack, New Jersey · Recruiting
University of Rochester Medical Center
Rochester, New York · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.